Crescent Grove Advisors LLC Makes New $200,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Crescent Grove Advisors LLC bought a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,704 shares of the medical research company’s stock, valued at approximately $200,000.

Other large investors also recently made changes to their positions in the company. Public Sector Pension Investment Board increased its holdings in shares of Edwards Lifesciences by 73.6% during the second quarter. Public Sector Pension Investment Board now owns 23,267 shares of the medical research company’s stock worth $2,149,000 after purchasing an additional 9,863 shares during the period. Algert Global LLC increased its stake in Edwards Lifesciences by 38.4% during the 2nd quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock worth $426,000 after acquiring an additional 1,280 shares during the period. Magnolia Capital Advisors LLC acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $834,000. Nemes Rush Group LLC lifted its position in shares of Edwards Lifesciences by 17.7% during the 2nd quarter. Nemes Rush Group LLC now owns 10,969 shares of the medical research company’s stock valued at $1,013,000 after acquiring an additional 1,651 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Edwards Lifesciences by 1.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 423,894 shares of the medical research company’s stock worth $39,155,000 after purchasing an additional 6,093 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.1 %

Shares of NYSE EW opened at $68.98 on Monday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company’s 50 day moving average price is $72.33 and its 200-day moving average price is $70.52. The company has a market capitalization of $40.68 billion, a P/E ratio of 9.95, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the business posted $0.59 EPS. The business’s revenue was up 8.9% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on EW. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.